Abstract
The AS/AGU rat provides an alternative to experimentally produced laboratory models of basal ganglia disorders. This mutant is characterised by disturbances of movement including clumsy gait, whole body tremor, rigidity and difficulty in initiating movement. From an early age, there is a profound depletion of extracellular dopamine in the dorsal caudate-putamen as measured via in vivo microdialysis; levels are only 10–20% of those found in the parent Albino Swiss (AS) strain. Subsequently a depletion of whole tissue dopamine levels occurs and, later still, loss of dopaminergic cells in the substantia nigra pars compacta. The dysfunction in movement and the nigrostriatal dopaminergic system are clearly linked, since movement can be ameliorated by L-DOPA administration. Furthermore, there are depletions in glucose utilisation in several regions of the basal ganglia circuitry, including the substantia nigra pars compacta, the subthalamic nucleus and the ventrolateral thalamus. The AS/AGU rat represents a unique opportunity to investigate the intrinsic factors controlling the integrity of dopaminergic systems and the recent successful positional cloning of the agu gene will allow the molecular mechanisms underlying this interesting phenotype to be analysed.
Keywords: AS/AGU rat, nigrostriatal dopaminergic system
Full Text
The Full Text of this article is available as a PDF (170.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bandmann O., Marsden C. D., Wood N. W. Genetic aspects of Parkinson's disease. Mov Disord. 1998 Mar;13(2):203–211. doi: 10.1002/mds.870130203. [DOI] [PubMed] [Google Scholar]
- Berman S. B., Zigmond M. J., Hastings T. G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem. 1996 Aug;67(2):593–600. doi: 10.1046/j.1471-4159.1996.67020593.x. [DOI] [PubMed] [Google Scholar]
- Bezard E., Imbert C., Gross C. E. Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci. 1998;9(2):71–90. doi: 10.1515/revneuro.1998.9.2.71. [DOI] [PubMed] [Google Scholar]
- Campbell J. M., Gilmore D. P., Russell D., Growney C. A., Favor G., Weir J., Stone T. W., Payne A. P. Extracellular levels of dopamine and its metabolite 3,4-dihydroxy-phenylacetic acid measured by microdialysis in the corpus striatum of conscious AS/AGU mutant rats. Neuroscience. 1998 Jul;85(2):323–325. doi: 10.1016/s0306-4522(98)00053-0. [DOI] [PubMed] [Google Scholar]
- Campbell J. M., Payne A. P., Gilmore D. P., Byrne J. E., Russell D., McGadey J., Clarke D. J., Davies R. W., Sutcliffe R. G. Neostriatal dopamine depletion and locomotor abnormalities due to the Albino Swiss rat agu mutation. Neurosci Lett. 1996 Aug 9;213(3):173–176. doi: 10.1016/0304-3940(96)12852-4. [DOI] [PubMed] [Google Scholar]
- Clarke D. J., Payne A. P. Neuroanatomical characterization of a new mutant rat with dopamine depletion in the substantia nigra. Eur J Neurosci. 1994 May 1;6(5):885–888. doi: 10.1111/j.1460-9568.1994.tb01000.x. [DOI] [PubMed] [Google Scholar]
- Cohen G., Farooqui R., Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A. 1997 May 13;94(10):4890–4894. doi: 10.1073/pnas.94.10.4890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gasser T. Genetics of Parkinson's disease. Clin Genet. 1998 Oct;54(4):259–265. doi: 10.1034/j.1399-0004.1998.5440401.x. [DOI] [PubMed] [Google Scholar]
- Grafton S. T., Mazziotta J. C., Pahl J. J., St George-Hyslop P., Haines J. L., Gusella J., Hoffman J. M., Baxter L. R., Phelps M. E. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol. 1990 Nov;28(5):614–621. doi: 10.1002/ana.410280503. [DOI] [PubMed] [Google Scholar]
- Graham D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 1978 Jul;14(4):633–643. [PubMed] [Google Scholar]
- Hastings T. G., Lewis D. A., Zigmond M. J. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol. 1996;387:97–106. doi: 10.1007/978-1-4757-9480-9_13. [DOI] [PubMed] [Google Scholar]
- Lam A. G., Campbell J. M., Bennett N. K., Payne A. P., Davies R. W., Sutcliffe R. G., McCulloch J. Local cerebral glucose utilization in the AS/AGU rat: a mutant with movement disorders. Eur J Neurosci. 1998 Jun;10(6):1963–1967. doi: 10.1046/j.1460-9568.1998.00206.x. [DOI] [PubMed] [Google Scholar]
- Leenders K. L., Salmon E. P., Tyrrell P., Perani D., Brooks D. J., Sager H., Jones T., Marsden C. D., Frackowiak R. S. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990 Dec;47(12):1290–1298. doi: 10.1001/archneur.1990.00530120034007. [DOI] [PubMed] [Google Scholar]
- Mouton L. J., VanderHorst V. G., Holstege G. Large segmental differences in the spinal projections to the periaqueductal gray in the cat. Neurosci Lett. 1997 Nov 28;238(1-2):1–4. doi: 10.1016/s0304-3940(97)00714-3. [DOI] [PubMed] [Google Scholar]
- Payne A. P., Sutcliffe R. G., Campbell J. M., Favor G., Russell D., Bennett N. K., Clarke D. J., Branton R., Davies R. W., Simpson E. Disordered locomotion in the AS/AGU mutant rat and the effects of L-dopa or fetal midbrain grafts. Mov Disord. 1998 Sep;13(5):832–834. doi: 10.1002/mds.870130514. [DOI] [PubMed] [Google Scholar]
- Shiels P., Durán Alonso M. B., Davidson A. O., Heeley R. P., Dominiczak A. F., Payne A. P., Davies R. W., Sutcliffe R. G. Optimized protocols for typing 75 microsatellite loci in AS, PVG, F344, and BN rats. Mamm Genome. 1995 Mar;6(3):214–215. doi: 10.1007/BF00293018. [DOI] [PubMed] [Google Scholar]
- Stokes A. H., Hastings T. G., Vrana K. E. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res. 1999 Mar 15;55(6):659–665. doi: 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]